Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 15/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666704 | 0.85 | ALDH1A1 (0.40) | HRH4HRH3HTR3AHPGDHTT | |
| SCHEMBL3672462 | 0.85 | HRH4 (0.36) | HRH4HRH3HTR3AHPGDHTT | |
| SCHEMBL3668071 | 0.84 | HPGD (0.38) | HRH4HRH3HTR3AHPGDHTT | |
| SCHEMBL3670195 | 0.80 | KDM4E (0.40) | HRH4HRH3HTR3AHPGDHTT | |
| SCHEMBL4104835 | 0.79 | TBXA2R (0.38) | HPGDHTTHSD17B10 | |
| SCHEMBL3666329 | 0.79 | TLR8 (0.37) | HRH4HRH3HTR3AHPGDHTT | |
| SCHEMBL3668176 | 0.78 | CCR9 (0.35) | HRH4HRH3HTR3AHPGDHTT | |
| SCHEMBL3666328 | 0.78 | BACE1 (0.36) | HRH4HRH3HTR3AHPGDHTT | |
| SCHEMBL3667095 | 0.78 | PSEN1 (0.39) | HRH4 | |
| SCHEMBL3675941 | 0.78 | KMT2A (0.42) | HRH4HRH3HTR3AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | claimed |
| EP-2139478-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Incorporated (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008121333-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-10-09 | — | — | WO | claimed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | claimed |
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2139478-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Incorporated (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121333-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121333-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | TNNC1, TNNI3, TNNT2 | HRH4 4875/4885HRH3 4669/4885HTR3A 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.